Advanced search
Publication Cover
Ophthalmic Epidemiology Volume 25, 2018 - Issue 2
Submit an article Journal homepage
390
Views
17
CrossRef citations to date
0
Altmetric
Original Articles

Risk Factors for Discontinuation of Treatment for Neovascular Age-Related Macular Degeneration

Inger WestborgDepartment of Clinical Sciences/Ophthalmology, Umeå University, Umeå, Sweden
&
Aldana RossoCentre of Registers South, Skåne University Hospital, Lund, Sweden, and Radiology Diagnostics, Institution of Translational Medicine, Lund University, Malmö, SwedenCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-6603-2855
ORCID Icon
Pages 176-182 | Received 14 Aug 2017, Accepted 04 Oct 2017, Published online: 13 Nov 2017

References

  • Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655.
  • Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New England J Med. 2006;355(14):1419–1431.
  • Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548.
  • Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121(5):1092–1101.
  • Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226.
  • Westborg I, Albrecht S, Rosso A. Risk for low visual acuity after 1 and 2 years of treatment with ranibizumab or bevacizumab for patients with neovascular age-related macular degeneration. Retina. 2017;37(11):2035–2046. doi:10.1097/IAE.0000000000001431.
  • Souied EH, Oubraham H, Mimoun G, Cohen SY, Quere S, Derveloy A. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the TWIN study. Retina. 2015;35(9):1743–1749.
  • Lad EM, Hammill BG, Qualls LG, Wang F, Cousins SW, Curtis LH. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. Am J Ophthalmol. 2014;158(3):537–543.e532.
  • Kruger Falk M, Kemp H, Sorensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol. 2013;155(1):89–95.e83.
  • Inger Westborg SA, Karlsson N, Libert C, Lövestam-Adrian M. Annual report Swedish Macula Register Swedish Macula Register; 2015.
  • Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046–1050. doi:10.1097/IAE.0b013e3181d87e04.
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8.
  • Lemon SC, Roy J, Clark MA, Friedmann PD, Rakowski W. Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med. 2003;26(3):172–181.
  • Oishi A, Mandai M, Nishida A, Hata M, Matsuki T, Kurimoto Y. Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration. Eur J Ophthalmol. 2011;21(6):777–782.
  • Curtis LH, Hammill BG, Qualls LG, et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. Am J Ophthalmol. 2012;153(6):1116–1124.e1111.
  • Sarwar S, Clearfield E, Soliman MK, et al. Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2016;2:CD011346.
  • L L-Am R, Schroeder M. Recommendation of treatment of neovascular age-related macula degeneration at Skåne county. In: Lund, Sweden: Skåne county; 2014.
  • Df M, Mg M, Sl F, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398.
  • Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908.
  • Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–1056.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.